Getting GLP-1s in Europe right now: the four real paths

Semaglutide and tirzepatide are the most clinically validated peptides on the market, by orders of magnitude. Getting them in Europe legally is a different question, and the answer changes at every border.

Here is the short version. The brand-name drugs are approved and available by prescription across the EU. Everything cheaper than that sits in a gray zone that 27 countries police 27 different ways. And retatrutide, the triple agonist everyone is waiting on, is not approved anywhere in Europe yet.

What is actually legal: the brand-name prescription

Semaglutide (sold as Ozempic and Wegovy) and tirzepatide (Mounjaro and Zepbound) have EMA approval. A doctor in France, Germany, or anywhere in the EU can write a prescription and a pharmacy will fill it. That is the clean path, and for most people it is the only one without legal exposure.

The catch is access, not legality. Approval for weight loss is narrower than approval for type 2 diabetes, supply has been tight, and the cash price is high. That gap is what pushes people toward the other three paths.

The four paths, ranked by risk

1. Branded prescription. Ozempic/Wegovy, Mounjaro/Zepbound. Lowest risk, highest cost. UK telehealth clinics have normalized semaglutide at roughly £150 to £250 a month; on the continent you are usually going through a GP or a private clinic.
2. Compounded through a pharmacy. A narrow, real path. It needs an individual prescription and a compounding (magistral) exception, and most pharmacists will not touch anything past the brand-name molecules. In the Netherlands the magistral rule genuinely allows per-patient preparation; in France almost no pharmacist will.
3. Registered "research" vendors. The EU sites that look legitimate: real companies, card payments, fast domestic shipping. They charge roughly 10x the source price, and what you are buying is risk-absorption and convenience, not a cleaner molecule. In France, selling this way is exercice illégal de la pharmacie, a criminal offense, not a paperwork problem. The corporate registration does not change that.
4. Direct from China. Cheapest by far. A monthly dose can run under $100 against $200 to $500 compounded and $700 to $1,200 branded. It is also where the quality falls apart: independent testing has found label-versus-actual dose diverging by as much as 43 percent, on top of customs seizures and zero clinical oversight.

It is fragmented, not free

The common belief is that Europe is looser than the US on peptides. It is not looser. It is fragmented. One community regular put it cleanly: in the US it is clearer even if it is stricter; in the EU it is a gray zone that changes country to country. What is possible in one place is impossible next door.

A quick map of the extremes:

• France: the hardest jurisdiction. Selling is criminal, ANSM does not recognize the "research only" frame, and declared shipments from outside the EU get seized at a high rate (anecdotal reports run near 50 percent).
• Germany: more workable. A private prescription (§21 AMG) can cover semaglutide or tirzepatide off-label.
• UK: the most developed telehealth market, with established semaglutide pricing.
• Switzerland: strict but predictable, with a low seizure rate (under 3 percent) and premium pricing.

Retatrutide: not yet

Retatrutide is the triple agonist (GLP-1, GIP, and glucagon) posting the strongest weight-loss numbers in trials. It is investigational. It has no EMA approval, and approval is not expected until roughly 2027 to 2028. Anything selling it today is selling an unapproved compound, and independent labs flag it as the most variable of the three in testing. Worth watching, not a current access path.

How we think about it

Ouros Lab does not prescribe and does not sell you a shortcut. The medicine belongs to you and a clinician; our job is to make the landscape legible so you can make an informed call with a doctor who signs the plan. If you are weighing the gray-market paths, the single most useful skill is verifying what you actually received. Start with how to vet a source, then read the country-by-country breakdown in Peptide legality in the EU and why EU and US rules diverge. More of our work is on the main feed.

The honest summary: if you can get a real prescription, the legal path costs more but removes almost all the risk. Every step away from it trades money saved for risk you now carry yourself.